Insulin and the Eyes: Systemic Benefits, Experimental Uses, and Risks

Insulin affects the eye primarily through systemic glycemic control; direct intraocular injection is experimental (not standard).

Systemic Effects (Diabetes Context)

  • Hypoglycemia: Blurred vision, diplopia, confusion – reversible with glucose.
  • Chronic Hyperglycemia → Retinopathy: Microaneurysms, hemorrhages, exudates, neovascularization (PDR), macular edema (DME). Insulin therapy reduces progression (DCCT/UKPDS).
  • Cataracts: Diabetes increases risk (sorbitol pathway); insulin mitigates by improving control. No direct causation.
  • Glaucoma: Diabetes increases risk (neovascular, open‑angle); insulin not causative.

Intravitreal Insulin (Experimental)

Studied for DME (insulin receptors on retinal cells). Not approved; risks: hypoglycemia, fibrosis, endophthalmitis.

Clinical Bottom Line

Proper insulin therapy protects the eye by achieving glycemic targets. Ocular side effects stem from dysglycemia, not insulin itself. Regular dilated eye exams are essential.

Eye & Vision Disorders - Related Articles